InnoSer
Private Company
Funding information not available
Overview
InnoSer is a specialized preclinical CRO leveraging deep expertise in complex therapeutic areas like neuroscience and oncology to support biotech and pharma clients. Its business model is built on providing customized, end-to-end research services from discovery optimization through in vivo studies, with a strong emphasis on its curated preclinical ecosystem and model validation. The company serves over 200 customers globally, differentiating itself through flexible, transparent collaboration and dedicated project management. Recent initiatives, like the partnership with Carthera for CNS drug delivery, demonstrate its focus on integrating advanced technological platforms.
Technology Platform
Integrated preclinical service ecosystem featuring validated in vivo models across multiple disease areas, specialized facilities for complex procedures, a partnership for the SonoCloud® ultrasound CNS drug delivery platform, custom model generation/colony management, and discovery support services (in vitro assays, organoids, imaging).
Opportunities
Risk Factors
Competitive Landscape
Competes with large, full-service global CROs (e.g., Charles River, Labcorp) and smaller, specialized European preclinical CROs. Differentiates through a deep therapeutic area focus, a flexible 'scientist-to-scientist' model, and unique technology access like the SonoCloud platform for CNS delivery.